Sana Biotechnology Inc SANA

$2.72 -0.03 (-1.09%)

Valuation

Market cap
862,160,000
Revenue TTM
$0
Net income TTM
$-244,170,000
PE ratio
0.00
Forward PE
—
Profit margin
0.00%
Debt to equity
0.00

Trading

Volume
4,314,700
Avg volume
3,237,640
Day's range
$2.70 – $2.85
Shares out
299,361,000
Stochastic %K
3%
Beta
2.18
Analysts
Strong Sell
Price target
$9.38

Price

Company profile

Sana Biotechnology, Inc., a biotechnology company, focuses on utilizing engineered cells as medicines in the United States. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including type 1 diabetes, B cell mediated autoimmune diseases, and oncology. The company's product pipeline includes UP421, a HIP-modified allogeneic primary islet cell product,...

Show more

Sana Biotechnology, Inc., a biotechnology company, focuses on utilizing engineered cells as medicines in the United States. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including type 1 diabetes, B cell mediated autoimmune diseases, and oncology. The company's product pipeline includes UP421, a HIP-modified allogeneic primary islet cell product, which is in phase 1 clinical trial to treat type 1 diabetes; SC451, a HIP-modified, stem cell derived pancreatic islet cell therapy, which is in preclinical trial for the treatment of type 1 diabetes; SG293 and SG299, a CD8-targeted fusosome for the treatment of B cell hematologic malignancies and B cell mediated autoimmune diseases. The company has an option and license agreement with Beam Therapeutics Inc. for use of Beam's proprietary CRISPR Cas12b nuclease editing technology to research, develop, and commercialize engineered cell therapy products; and a license agreement with Harvard College to access certain intellectual property for the development of hypoimmune-modified cells. The company has a strategic collaboration with Mayo Clinic for the development of SC451, a hypoimmune-modified pancreatic islet cell therapy for type 1 diabetes. The company was formerly known as FD Therapeutics, Inc. and changed its name to Sana Biotechnology, Inc. in September 2018. Sana Biotechnology, Inc. was incorporated in 2018 and is headquartered in Seattle, Washington.

Industry
Biotechnology
Sector
Healthcare
Phone
206 701 7914
Website
https://www.sana.com
Address
188 East Blaine Street, Suite 400, Seattle, United States

Latest news

Stocktwits

cta7978 Oct 7, 10:51 PM
$SANA SANA BIOTECHNOLOGY CO-FOUNDER GEOFFREY VON MALTZAHN SET TO JOIN PRESIDENT TRUMP AT WHITE HOUSE “SCIENCE: A NEW GOLDEN AGE” SUMMIT (Posted on X - not confirmed)
0 replies
Logic102 Oct 6, 2:57 PM
$LCTX If/when Lineage continues to prove its ability to scale high-quality Islet Cells far beyond the competition, 862M M Cap $SANA and much larger 127.6B $VRTX and even the GLP-1 Behemoths Lilly, NovoNordisk and Sanofi need to start paying serious attention. BlueRock (Bayer) and Astellas also will soon need what Lineage can supply if they are going to make continued progress. All of this is being totally ignored by the broader market at this point.
1 replies
_DannyGh8st Oct 6, 1:48 AM
$SANA Potential one-time treatment for Type 1 diabetes Phase 1/2 expected in 2026..
0 replies
NoJobRob Oct 5, 10:46 PM
$SANA Considering the markets muted/mostly flat reaction, I'm assuming that whatever was presented at Fridays EASD presentation was "as expected" Has anyone found any details?
0 replies
Merlintrader Oct 5, 5:52 PM
Sana Biotechnology ($SANA): Can UP421 Support the Next Clinical Step? UP421 human evidence, SC451 and SG293 milestones, cash burn and share issuance. Explore the company, catalysts and risks in our research hub. https://www.merlintrader.com/sana-biotechnology-sana-stock-hub/
0 replies
BriOnH Oct 3, 4:03 PM
$SANA I initiated a stake in $IPSC yesterday, and will be DCA for the next month into it. Their 29 day manufacturing and cold storage for transport has piqued my interest enough to invest. I am also very concerned right now they beat Sana to the punch of the first person cured, BUT fact is they carry more risk with it even working in human. My T1D Investments according to size right now: 1)$SANA - by far the largest, and plan to add more as data progresses. 2)$ELDN - Decent chunk. Tego is the ultimate back up, and I see it as a very important gap filler between HIP islets to kidneys, to livers, to lungs, to hearts, and anything else that is going to take time to develop over the next 2-3 decades. Current immunosuppression, Tacrolimus, is toxic and the side effects suck. God forbid with my very progressed CKD, I also may need tego for a kidney someday. I pray not though. 3)$IPSC Micro 1-2% of $ at most. F!!! I maybe picked the wrong horse play as a 50 yr T1D science man. GLA
2 replies
JerryMalone32 Oct 3, 3:15 PM
$SANA thanks for all the input, CTA and Brian, etc. it also seems to be driven by economics. If a high percentage of cells are destroyed right away after being put in the liver, that means Sana would have to increase ots dose to account for that. Then, Sana would be treating a far less # of patients which is a huge problem since it will be capacity constrained for years, anyway, as it scales up.
1 replies
BBraggHillBoys Oct 3, 12:10 PM
$SANA Milan headline: Can HIP-engineered pancreatic cells survive and function inside a human without immunosuppression? So far: very encouraging evidence that they can.
0 replies